Atopic Dermatitis (Eczema)

A chronic, pruritic inflammatory skin disease fundamentally rooted in epidermal barrier dysfunction.

The Defective Barrier

The stratum corneum operates similarly to a "brick and mortar" wall. The corneocytes are the bricks, and the intercellular lipids (ceramides, cholesterol, free fatty acids) are the mortar.

In atopic dermatitis, this barrier is structurally compromised, frequently due to a genetic mutation in the filaggrin gene, which is essential for corneocyte structural integrity and the generation of Natural Moisturizing Factor (NMF).

The Cycle of Inflammation

A compromised barrier leads to two primary issues:

1. Increased Transepidermal Water Loss (TEWL): The skin cannot retain moisture, leading to profound xerosis (dryness).
2. Allergen Penetration: Environmental antigens and pathogens (like S. aureus) easily penetrate the skin, triggering a robust Th2 immune response, leading to intense pruritus (itching) and clinical lesions.

Clinical Management

Therapy focuses on restoring the lipid barrier and suppressing the inflammatory cascade.

• Physiological Lipid Replacement: Utilizing moisturizers formulated with a 3:1:1 ratio of Ceramides, Cholesterol, and Free Fatty Acids to mimic endogenous skin lipids.
• Occlusion: Applying inert, occlusive agents like petrolatum (Vaseline) overnight to artificially halt TEWL and create a permissive environment for barrier repair.
• Anti-inflammatory Agents: Topical Corticosteroids (for acute flares), Calcineurin Inhibitors (Tacrolimus/Pimecrolimus) for steroid-sparing maintenance.